Raaflaub J
Schweiz Med Wochenschr. 1980 Mar 8;110(10):354-62.
A survey of the various aspects of the concept of bioavailability of orally administered drugs is presented. Oral bioavailability may be less than complete as a result of one of three main situations: incomplete absorption due to very slow and/or incomplete dissolution of the drug in the gastrointestinal tract, incomplete absorption due to poor permeability of the drug through the intestinal epithelia, and biotransformation of the drug during its first passage through the liver. This latter so-called first-pass effect is discussed in details. The main clinical concern of a substantial first-pass effect lies in the frequently observed large interindividual variability of the effect. This results in unduly variable drug-concentrations in the blood of patients treated by the same oral standard dosage. The mechanism of this phenomenon is outlined and referred to a shift of the drug metabolising reactions in the liver from first-order type to Michaelis-Menten type during the absorption phase. As to the significance of the oral bioavailability of a drug in human pharmacotherapy, the clinical impact of bioavailability should not be overemphasized. It should rather be judged and considered in the light of the different aspects of the pharmacodynamic potency of the drug. This, however, implies that the physician is acquainted with the main mechanisms involved in the impairment of oral availability.
本文对口服给药生物利用度概念的各个方面进行了综述。由于以下三种主要情况之一,口服生物利用度可能不完全:药物在胃肠道中溶解非常缓慢和/或不完全导致吸收不完全;药物通过肠上皮的渗透性差导致吸收不完全;药物在首次通过肝脏时发生生物转化。本文将详细讨论后一种所谓的首过效应。首过效应显著的主要临床问题在于经常观察到的个体间效应的巨大差异。这导致接受相同口服标准剂量治疗的患者血液中的药物浓度过度变化。本文概述了这一现象的机制,并将其归因于吸收阶段肝脏中药物代谢反应从一级反应类型向米氏反应类型的转变。至于药物口服生物利用度在人类药物治疗中的意义,生物利用度的临床影响不应被过分强调。而应根据药物药效学效力的不同方面进行判断和考虑。然而,这意味着医生要熟悉口服生物利用度受损的主要机制。